Get started
Author

Katherine Cintron

Observed names: Katherine Cintron-Lue, Katherine Cintron‐Lue
Observed institution: PTC Therapeutics (United States)
ORCID: 0000-0003-4190-1609
Observed ORCID: 0000-0003-4190-1609
OpenAlex ID: A5032141712
BMI1 as a novel target for drug discovery in cancer
2011 · Liangxian Cao, Jenelle Bombard, et al. · Journal of Cellular Biochemistry · 137
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
2018 · Liangxian Cao, Marla Weetall, et al. · Molecular Cancer Therapeutics · 91
The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines
2020 · Jeremy Luban, Rachel A. Sattler, et al. · Virus Research · 74
PDF
Discovery and SAR Studies of Potent Modulators of BMI‐1 Expression
2023 · Ramil Y. Baiazitov, Nadiya Sydorenko, et al. · Helvetica Chimica Acta
PDF
Data from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
2023 · Liangxian Cao, Marla Weetall, et al.
Data from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
2023 · Liangxian Cao, Marla Weetall, et al.
Supplementary Figures S1-S7; Supplementary Tables S1-S7; and Supplementary Materials and Methods from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
2023 · Liangxian Cao, Marla Weetall, et al.
Supplementary Excel file-1 from Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties
2023 · Liangxian Cao, Marla Weetall, et al.
Works count: 8
Citation count: 302
H-index: 3
I10-index: 3
Year
Topic
Type